Chimerix is a biotechnology company developing therapeutics for antiviral diseases.
Führungspositionen
Name & Titel
Biographie
M. Michelle Berrey
CEO / President
Dr. M. Michelle Berrey, M.D., MPH, has been the Chief Executive Officer and President of Chimerix, Inc. since April 09, 2014. Dr. Berrey has been the Chief Medical Officer of Chimerix, Inc. since November 12, 2012 until September 02, 2014. Dr. Berrey served as the Chief Medical Officer of Pharmasset, Inc. from January 24, 2007 to January 2012. Dr. Berrey served as Vice President of Viral Diseases, Clinical Pharmacology and Discovery Medicine of GlaxoSmithKline. Dr. Berrey was responsible for the early development and clinical strategy of Phase I-2a studies for new targets against HIV, hepatitis viruses and hepatic fibrosis at GlaxoSmithKline. Her experience includes the design, early development, medical governance, clinical strategy and product life cycle management for antiviral products and she has simultaneously managed multiple clinical trials across all phases of development. She was a Senior Fellow in Infectious Disease Medicine at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. Dr. Berrey has been a Director of Chimerix, Inc. since June 2014. Dr. Berrey received a Master of Public Health from Emory University and she received her M.D. from the Medical College of Georgia. She completed her Internship and Residency in Internal Medicine at the University of North Carolina, Chapel Hill.
Lisa Ricciardi
Non-Executive Director
Ms. Lisa R. Ricciardi has been Non-Executive Director of UDG Healthcare plc since June 14, 2013. Ms. Ricciardi was Senior Vice President of Foundation Medicine, Inc. and prior to this was Senior Vice President of US and International Business Development at Medco Health Solutions. She also held multiple senior roles in Pfizer, first in operations then leading business development for over a decade. Ms. Ricciardi joined Essex Woodlands in October 2007. She holds a Bachelor of Arts from Wesleyan University and a Master of Business Administration from the University of Chicago.
Timothy W. Trost CPA
Senior VP, CFO & Corporate Secretary
Mr. Timothy W. Trost, CPA, has been the Chief Financial Officer of Chimerix, Inc. since March 28, 2011. Mr. Trost has been the Senior Vice President and Corporate Secretary at Chimerix, Inc. since February 2012. Mr. Trost has more than 30 years of experience in the financial field. Mr. Trost served as Chief Financial Officer and Vice President of Argos Therapeutics, Inc. (formerly MERIX Bioscience, Inc) until February 23, 2010. Mr. Trost joined MERIX in July 2002. Prior to joining MERIX, he served as Senior Vice President and Chief Financial Officer of InteCardia, Inc., a venture-backed cardiology development firm sold to Syncor International in August 2001. Prior to InteCardia, he served as senior vice president of corporate development and executive vice president and chief financial officer of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians. Prior to that, he served as vice president of finance / controller of Morganite North America, Inc., the US holding company of The Morgan Crucible Company PLC (London exchange). Mr. Trost began his professional career with a total of twelve years (in four offices) at the international accounting and consulting firm of Price Waterhouse. Mr. Trost holds a degree in accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
Linda M. Richardson
Chief Strategy & Commercial Officer
Ms. Linda M. Richardson has been a Chief Strategy and Commercial Officer of Chimerix, Inc since April 2017 and served as its Chief Commercial Officer from January 2014 to April 2017. Ms. Richardson served as Vice President and Head of the Global lixisenatide franchise, leading the commercial worldwide launch of Lyxumia, a new injectable drug for Type 2 diabetes. While at Sanofi, she also led the pre-launch strategy development for several other products and reinvigorated Multaq performance in the U.S. Prior to joining Sanofi, Ms. Richardson served as Vice President of Marketing of Reliant Pharmaceuticals, Inc. Ms. Richardson joined Reliant in January 2005 as Product Director responsible for the launch of Omacor, following over 18 years experience in the pharmaceutical industry, primarily at GlaxoSmithKline. Her career began as a Glaxo sales representative promoting the respiratory portfolio and then moved into market research, where she managed the launch research in support of Flonase. She served as the Manager of the respiratory market research team. Following this role, she launched the first non-nicotine agent for smoking cessation, Zyban, including a major DTC campaign and a multi-million dollar patient behavioral modification program. Additional roles of increasing marketing responsibility included the launch of the anti-viral Relenza, work on Requip for Parkinson's disease and commercializing Requip as the first FDA-approved product for Restless Legs Syndrome. Ms. Richardson served on the Board of Directors of Healthy Women, a non-profit organization dedicated to promoting health and wellness among women. In 2008, she was nominated by her peers as one of the 100 Most Inspiring Leaders in the Life Sciences field and labeled as a Market Maker in PharmaVoice magazine and in 2011 she was given the Rising Star award by the Healthcare Businesswomen's Association. Ms. Richardson received a B.A. in English from the University of Pennsylvania.
William Garrett Nichols M.D., MS
Chief Medical Officer
Dr. William Garrett Nichols, M.D., MS, has been the Chief Medical Officer of Chimerix, Inc. since September 02, 2014. Dr. Nichols joined the Chimerix, Inc. from ViiV Healthcare, where he was the Head of Global Development. Prior to his tenure at ViiV, Dr. Nichols spent ten years at GlaxoSmithKline leading multiple global antiviral programs in the United States and Europe, including the development and regulatory submissions to the U.S. Food and Drug Administration (the FDA) and the European Medicines Agency for the approval of Tivicay and the recent FDA approval of Triumeq. Dr. Nichols spent four years on the faculty of the Fred Hutchinson Cancer Research Center in Seattle, WA, where he was the principal investigator on NIH-funded grants exploring the prevention and treatment of CMV and respiratory virus infections in HCT recipients. Dr. Nichols received his M.D. from Duke University and earned an M.S. in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.
Joseph F. Rutledge
VP of Information Technology & Chief Information Officer
Mr. Joseph F. Rutledge, also known as Joe, has been the Chief Information Officer and Vice President of Information Technology at Chimerix, Inc. since 2015. Mr. Rutledge has more than 35 years of experience in the design, development and deployment of large-scale hardware and software systems. Mr. Rutledge's broad-based business, technical and managerial background in software and hardware engineering and production development environments spans several industries including entertainment, aircraft, aerospace, undersea and steel manufacturing. He served as the Chief Technical Officer of ViOS, Inc. (Also known as Viewpoint Corporation). He served as the Chief Information Officer at Trimeris. He served as Vice President of Technology at Practicing Smarter. He joined Chimerix in 2013. He served as Director of Information Technology at Kainos Medicine. He was a Co-Founder and Senior Vice President of Technology at iEntertainment Network. Mr. Rutledge has a BS in Mathematics from the University of Pittsburgh.
Michael A. Alrutz J.D., Ph.D.
Senior VP & General Counsel
Dr. Michael A. Alrutz, J.D., Ph.D., has been Senior Vice President and General Counsel of Chimerix, Inc. since August 29, 2015 and September 2014 respectively. Dr. Alrutz served as Corporate Counsel at Chimerix, Inc. since 2012. Dr. Alrutz joined Chimerix in 2012. He served as General Counsel of Trimeris Inc. since January 24, 2008. He served as Legal Counsel of Trimeris since 2002 until 2011. Dr. Alrutz received his B.A. degree in Biology from the University of Pennsylvania and his J.D. from Duke University School of Law. He also holds a Ph.D. in Molecular Biology from the Sackler School of Graduate Biomedical Sciences at Tufts University.
Timothy Trost
Senior Vice President, Chief Financial Officer
Timothy Trost serves as the Senior Vice President, Chief Financial Officer of Chimerix, Inc.. Timothy started at Chimerix, Inc. in Jul of 2010. Timothy currently resides in the Raleigh-Durham, North Carolina Area.
Kevin Reeves
Vice President Sales Marketing
Kevin Reeves serves as the Vice President Sales Marketing of Chimerix, Inc.. Kevin started at Chimerix, Inc. in Dec of 2015. Kevin currently resides in the Raleigh-Durham, North Carolina Area.
April Knight-Trent
Vice President and Head of Regulatory Affairs
April Knight-Trent serves as the Vice President and Head of Regulatory Affairs of Chimerix, Inc.. April started at Chimerix, Inc. in September of 2017. April currently resides in the Greater New York City Area.
Lassen Sie Chimerix wissen, dass Sie dort arbeiten möchten
Sagen Sie Chimerix, dass Sie interessiert sind dort zu arbeiten, ihre persönlichen Informationen bleiben dabei anonym. Comparably gibt Chimerix die Gelegenheit, Sie anzustellen. Wenn es eine passende Stelle gibt, matchen wir diese.
Gleichberechtigungs BewertungWie positiv bewerten Frauen ihre Gesamterfahrung mit Chimerix
N/A
Herkunftsvielfalts BewertungWie positiv bewerten Minderheiten ihre Gesamterfahrung mit Chimerix